Gedeon Richter sees downturn in sales and earnings

8 November 2018

Hungary's largest drugmaker Gedeon Richter (RICHT: HB) today posted financial results, showing that consolidated sales at 323,875 million forint ($1.15 billion), EUR 1,020.9 million euros ($1.17 billion), declined in the first nine months 2018 by 10,278 million forint (-3.1%) and by 62.3 million euros (-5.8%) when compared with the same period 2017.

Gross profit in the first three quarters 2018 at 189,245 million forint (596.5 million euros) declined by 1.2% (down 3.9% in euro terms) when compared to the same period of the previous year. The gross margin increased by 110 basis points to 58.4% during the reported period. Basic earnings per share were 256 forint, up 6.7%.

Royalty proceeds resulting from sales of Vraylar (cariprazine) exceeded base period’s levels by 20.0 million euros or 61.9% ($26.6 million, 74.1%) and sales in China were 7.8 million euros, 14.7% above the levels recorded in the nine months to September 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK